AlphaGrep UK Ltd’s Bristol-Myers Squibb BMY Stock Holding History

AlphaGrep UK Ltd’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,205	Closed	-$712K	–	790
2025 Q4	$712K	Buy	+13,205	New	+$635K	0.24%	99

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaGrep UK Ltd's BMY Position: Q1 2026 in Review

AlphaGrep UK Ltd sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 13,205 shares — an estimated $712K sold.

AlphaGrep UK Ltd first reported a position in BMY in Q4 2025 and held it in 1 quarter. The position peaked at $712K in Q4 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

AlphaGrep UK Ltd reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
AlphaGrep UK Ltd sold 13,205 Bristol-Myers Squibb shares in Q1 2026, an estimated $712K.
AlphaGrep UK Ltd first reported a position in Bristol-Myers Squibb in Q4 2025 and held it in 1 quarter.
AlphaGrep UK Ltd's Bristol-Myers Squibb position peaked at $712K in Q4 2025.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.